Pramod Thomas is a senior correspondent with Asian Media Group since 2020, bringing 19 years of journalism experience across business, politics, sports, communities, and international relations. His career spans both traditional and digital media platforms, with eight years specifically focused on digital journalism. This blend of experience positions him well to navigate the evolving media landscape and deliver content across various formats. He has worked with national and international media organisations, giving him a broad perspective on global news trends and reporting standards.
KING CHARLES III and his wife Queen Camilla have made a brief stopover in India following their recent trip to Australia and Samoa, Buckingham Palace confirmed, staying at a holistic health centre they have visited before.
The royal couple stayed at the holistic health centre, known for rejuvenative treatment, including yoga and meditation sessions and therapies in Bengaluru in southern India, an official said.
They made a short restful stopover in the country to break their long journey back to the UK from the Commonwealth Heads of Government Meeting (CHOGM) in Samoa.
Indian media reported that the royal couple had arrived in Bengaluru on Oct. 27 and had since been at the Soukya International Holistic Health Centre, where they had enjoyed yoga and meditation sessions.
"Their majesties had a short private stopover in India to help break the long journey back from Samoa," a Buckingham Palace spokesperson said. "They return to the UK this morning."
Charles, who has long advocated alternative medicines and therapies, has paid many visits to India and to the Soukya centre itself before. He celebrated his 71st birthday there in 2019.
It is run by Dr Issac Mathai, who is among the few individuals from India invited to attend his coronation as the UK's King on May 6 last year.
"The couple underwent therapeutic yoga, enjoyed a strictly vegetarian diet with eggs. They underwent rejuvenative treatment, which also included meditation and therapies," an official at the facility said. "The King received wellness treatment, including Ayurveda, Homeopathy and Naturopathy."
Security personnel stand guard outside the Soukya International Holistic Health Centre (SIHHC) in Bengaluru on October 30, 2024. (Photo by IDREES MOHAMMED/AFP via Getty Images)
It was like a typical day for them just like for any other guest who visits the facility.
"Their day began with morning therapeutic yoga which is taught by a specialised doctor knowing the medical condition or any health issue if any. This was usually a one-on-one session. After breakfast, then treatment started which was followed by lunch," he said.
"Food was prepared from fresh organic produce from the farm at the campus and the evenings were more about meditation. That's how his days were here. This is done for every guest. The only difference is with each person's medical condition or their health issue, we fine tune it accordingly."
During the three-day stay, they also took a tour of the organic farming and medicinal garden, visited a cow shed, engaged in eco-friendly practices and walked on the grasses -- felt connected to nature as the campus is home to butterflies, dragon files, frogs and wild rabbits.
According to him, the King planted a Jacaranda sapling at a centrally located spot of the 30-acre campus during his visit.
Giving details about the treatment offered at the facility, the official said, "We have a philosophy of holistic wholesomeness. King Charles has been involved with that since the last 30-40 years and he was the patron of the British Association for Holistic Medicine and Healthcare.
"He (Charles) is the patron of the faculty of Homeopathy. So, he is actively involved in it and he believes in it. All these organic gardening and medical gardening, preservation, water harvesting system, solar panels, biogas plant all fascinate him."
A royal source said the stopover was not connected to his ongoing health issues, but was to allow him to rest as part of planning for the long-distance travel his recent tour had involved at a location he was familiar.
His cancer treatment will resume on his return to Britain, the source said.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.